Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 3Not yet recruiting 3Recruiting 2Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Chemotherapy-Induced Thrombocytopenia 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × hetrombopag × Clear all
NCT05864014 2025-04-16

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Active not recruiting
213 enrolled
Classical hematology

Chemotherapy-Induced Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡